Literature DB >> 12843194

Generation of anti-insulin-like growth factor-binding protein-related protein 1 (IGFBP-rP1/MAC25) monoclonal antibodies and immunoassay: quantification of IGFBP-rP1 in human serum and distribution in human fluids and tissues.

Abel López-Bermejo1, Javad Khosravi, Christopher L Corless, Radha G Krishna, Anastasia Diamandi, Umesh Bodani, Eric M Kofoed, Donna L Graham, Vivian Hwa, Ron G Rosenfeld.   

Abstract

The IGF-binding protein (IGFBP)-related proteins (rPs) are a group of recently described cysteine-rich proteins that share significant amino-terminal structural similarity with the conventional IGFBPs. IGFBP-rP1 (also known as MAC25/angiomodulin/prostacyclin-stimulating factor and T1A12), regulates cellular proliferation, adhesion, and angiogenesis and stimulates prostacyclin synthesis. We characterized new monoclonal antibodies generated against IGFBP-rP1 and have used them to study the distribution of IGFBP-rP1 in human biological fluids and tissues. Additionally, we have developed a noncompetitive sandwich-type immunoassay to quantitate the concentrations of IGFBP-rP1 in human serum. IGFBP-rP1 was readily detectable in serum, urine, amniotic fluid, and cerebrospinal fluid by immunoblot analysis. Evaluation of the newly developed immunoassay demonstrated acceptable analytical performance, with a detection limit of 0.7 micro g/liter, a dynamic range of 3.1-100 micro g/liter, and intra- and interassay coefficients of variation of 2.5-6.8% and 3.1-6.4% at approximately 24-85 ng/ml IGFBP-rP-1, respectively. No significant cross-reactivity with IGFBP-1-6 was observed. In random normal human adult sera (n = 37), the median IGFBP-rP1 was 21.0 micro g/liter, and values did not correlate with levels of IGF-I (r = 0.085, P = 0.61), IGF-II (r = 0.051, P = 0.75), or IGFBP-3 (r = 0.061, P = 0.74). The monoclonal anti-IGFBP-rP1 antibodies also readily detected IGFBP-rP1 expression in human tissue sections, with preferential expression of IGFBP-rP1 in the microvascular endothelium associated with tumorigenesis. In summary, using newly developed IGFBP-rP1 monoclonal antibodies, we confirm the presence of IGFBP-rP1 in the major human body fluids, provide quantitative normative data on the concentrations of IGFBP-rP1 in human serum, and show preferential expression of IGFBP-rP1 in the microvascular endothelium associated with tumorigenesis. The use of these novel IGFBP-rP1 detection tools should prove useful in the elucidation of the biological role(s) of this protein.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12843194     DOI: 10.1210/jc.2002-021315

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

1.  Proteomic analysis identifies insulin-like growth factor-binding protein-related protein-1 as a podocyte product.

Authors:  Takayuki Matsumoto; Sonja Hess; Hiroshi Kajiyama; Toru Sakairi; Moin A Saleem; Peter W Mathieson; Yoshihisa Nojima; Jeffrey B Kopp
Journal:  Am J Physiol Renal Physiol       Date:  2010-07-14

2.  Physiologic IGFBP7 levels prolong IGF1R activation in acute lymphoblastic leukemia.

Authors:  Leonardo Luís Artico; Angelo Brunelli Albertoni Laranjeira; Livia Weijenborg Campos; Juliana Ronchi Corrêa; Priscila Pini Zenatti; José Barreto Campello Carvalheira; Sandra Regina Brambilla; Alexandre Eduardo Nowill; Silvia Regina Brandalise; José Andrés Yunes
Journal:  Blood Adv       Date:  2021-09-28

3.  Transcriptomic profiling of a multiethnic pediatric NAFLD cohort reveals genes and pathways associated with disease.

Authors:  Kangning Yao; Elena Tarabra; Daniela Sia; Raffaella Morotti; Rima Fawaz; Pamela Valentino; Nicola Santoro; Sonia Caprio; Silvia Liu; Dean Yimlamai
Journal:  Hepatol Commun       Date:  2022-03-21

Review 4.  Insulin-like growth factor-1 deficiency and metabolic syndrome.

Authors:  G A Aguirre; J Rodríguez De Ita; R G de la Garza; I Castilla-Cortazar
Journal:  J Transl Med       Date:  2016-01-06       Impact factor: 5.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.